Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Eklira

This page shows the latest Eklira news and features for those working in and with pharma, biotech and healthcare.

AZ adds to respiratory portfolio with Actavis drugs

AZ adds to respiratory portfolio with Actavis drugs

It follows a similar deal agreed in July last year for AZ to buy the global respiratory portfolio of Almirall for $2bn, including the approved Eklira (aclidinium) for COPD and several

Latest news

  • AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

    Almirall's franchise includes Eklira (aclidinium), LAS40464 (a combination of aclidinium with formoterol, which has been filed in Europe), LAS100977 (abediterol), a once-daily phase II long-acting beta2-agonist (LABA),

  • Almirall expands in US via $400m deal to buy Aqua Almirall expands in US via $400m deal to buy Aqua

    under 22m on the back of high roll-out costs for new products such as Sativex (nabiximols) for spasticity in multiple sclerosis (MS) and chronic obstructive pulmonary disorder (COPD) treatment Eklira

  • IQWiG knocks back Almirall's Eklira IQWiG knocks back Almirall's Eklira

    A long-acting bronchodilator, Eklira is licensed to treat adults with chronic-obstructive pulmonary disease (COPD) and works by widening their narrowed airways. ... The cost effectiveness body was similarly scathing when it came to making indirect

  • Breathing easier

    While there are several therapies currently in late-stage clinical trials for COPD — including aclidinium bromide (Eklira, Almirall Prodesfarma/Forest Laboratories), vilanterol/fluticasone furoate (Relovair, GSK), andolast (Rottapharm Madaus) and

  • Almirall posts positive results

    Potential key growth drivers ahead include the Eklira franchise, linaclotide, which offers a pan-European first-in-class opportunity in late stage development, Sativex for which approval is expected in Q2,

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Quick links

Infographics

Multimedia